Indoco Remedies Ltd. announced the receipt of tentative approval from the USFDA for Abbreviated New Drug Application (ANDA) for Canagliflozin and Metformin Hydrochloride Tablets, 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg and 150 mg/1000 mg, a generic equivalent of Invokamet® Tablets, 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg and 150 mg/1000 mg. This product, Canagliflozin and Metformin Hydrochloride Tablets, will be manufactured by Indoco Remedies Limited, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa 403722 in India. Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
344.8 INR | +0.01% |
|
+5.67% | -12.74% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.74% | 381M | |
+55.55% | 816B | |
+40.32% | 634B | |
-6.83% | 351B | |
+17.15% | 323B | |
+7.09% | 293B | |
+14.04% | 238B | |
+1.35% | 222B | |
+13.61% | 218B | |
+7.87% | 167B |
- Stock Market
- Equities
- INDOCO Stock
- News Indoco Remedies Limited
- Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets